News Novartis hit as Lp(a) drug fails cardio outcomes trial Novartis shares slipped afterit revealed its Lp(a)-targeted drug, pelacarsen, failed to reduce cardiovascular risks in a major phase 3 trial.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
